The Medical Letter on Drugs and Therapeutics
IV Aprepitant (Cinvanti) for Chemotherapy-Induced Nausea and Vomiting (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved Cinvanti (Heron), an IV emulsion formulation of the substance P/neurokinin-1 (NK1) receptor antagonist aprepitant, for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Aprepitant is also available in oral capsule and suspension formulations (Emend, and generics), and fosaprepitant, a prodrug of aprepitant, is available in an IV formulation (Emend for injection).

STANDARD TREATMENT — Patients receiving moderately emetogenic chemotherapy are generally treated with dexamethasone (Decadron, and generics) and a 5-HT3 receptor antagonist such as palonosetron (Aloxi, and generics) for prevention of CINV; those receiving carboplatin-based chemotherapy should also receive a substance P/NK1 receptor antagonist (see Table 1). Most patients treated with ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: IV Aprepitant (Cinvanti) for Chemotherapy-Induced Nausea and Vomiting (online only)
Article code: 1561f
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian